NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said Monday that the investment from SHIFT Invest and Oost NL follows recent strong progress as well as its first significant commercial traction.

纽约——Scope Biosciences 已获得 100 万欧元（120 万美元）的后续投资，用于扩展其分子诊断平台。这家诊断开发公司周一表示，来自 SHIFT Invest 和 Oost NL 的投资是在近期取得显著进展以及首次实现重要的商业吸引力之后获得的。

.

。

The firm said its cumulative seed funding totals €6 million, including prior strategic and venture capital investments such as a €2.5 million European Innovation Council transition

该公司表示，其累计种子资金总额为 600 万欧元，其中包括之前的战略性投资和风险投资，例如欧洲创新委员会提供的 250 万欧元过渡资金。

grant

授予

last year and a €1 million

去年和100万欧元

investment

投资

from Gene Diagnostics in 2021.

来自2021年的基因诊断。

'We’re grateful for the continued backing of SHIFT and Oost NL, and proud to have secured significant public and private support as we bring our technology closer to market,' said Niek Savelkoul, CEO and founder of ScopeBio. Now, 'we're scaling up, building out our platform and getting ready to meet real-world diagnostic challenges head-on,' he added..

“我们感谢SHIFT和Oost NL的持续支持，并且自豪于在将技术推向市场的过程中获得了重要的公共和私人支持，”ScopeBio的首席执行官兼创始人Niek Savelkoul表示。他补充道：“现在，我们正在扩大规模，构建我们的平台，并准备迎接现实世界中的诊断挑战。”

Based in Wageningen, Netherlands, and a spinout of Wageningen University & Research, the firm said that its ScopeDx system uses CRISPR to deliver ultra-precise, single-nucleotide detection in a portable and field-ready format, without proprietary hardware or centralized labs, adding that the technology lends itself to both healthcare and agricultural applications.

总部位于荷兰瓦赫宁根，作为瓦赫宁根大学与研究中心的衍生公司，该公司表示其ScopeDx系统利用CRISPR技术，在便携式和现场适用的格式中实现超精确的单核苷酸检测，无需专用硬件或中心化实验室，并补充说该技术适用于医疗保健和农业应用。

.

。